Anti-FOLH1/ GCPII/ FGCP monoclonal antibody

Anti-FOLH1/ GCPII/ FGCP antibody for FACS & in-vivo assay

Target products collectionGo to GCPII/FOLH1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T97071-Ab-1/ GM-Tg-hg-T97071-Ab-2Anti-Human GCPII/FOLH1 monoclonal antibodyHuman
GM-Tg-rg-T97071-Ab-1/ GM-Tg-rg-T97071-Ab-2Anti-Rat GCPII/FOLH1 monoclonal antibodyRat
GM-Tg-mg-T97071-Ab-1/ GM-Tg-mg-T97071-Ab-2Anti-Mouse GCPII/FOLH1 monoclonal antibodyMouse
GM-Tg-cynog-T97071-Ab-1/ GM-Tg-cynog-T97071-Ab-2Anti-Cynomolgus/ Rhesus macaque GCPII/FOLH1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T97071-Ab-1/ GM-Tg-felg-T97071-Ab-2Anti-Feline GCPII/FOLH1 monoclonal antibodyFeline
GM-Tg-cang-T97071-Ab-1/ GM-Tg-cang-T97071-Ab-2Anti-Canine GCPII/FOLH1 monoclonal antibodyCanine
GM-Tg-bovg-T97071-Ab-1/ GM-Tg-bovg-T97071-Ab-2Anti-Bovine GCPII/FOLH1 monoclonal antibodyBovine
GM-Tg-equg-T97071-Ab-1/ GM-Tg-equg-T97071-Ab-2Anti-Equine GCPII/FOLH1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T97071-Ab-1/ GM-Tg-hg-T97071-Ab-2; GM-Tg-rg-T97071-Ab-1/ GM-Tg-rg-T97071-Ab-2;
GM-Tg-mg-T97071-Ab-1/ GM-Tg-mg-T97071-Ab-2; GM-Tg-cynog-T97071-Ab-1/ GM-Tg-cynog-T97071-Ab-2;
GM-Tg-felg-T97071-Ab-1/ GM-Tg-felg-T97071-Ab-2; GM-Tg-cang-T97071-Ab-1/ GM-Tg-cang-T97071-Ab-2;
GM-Tg-bovg-T97071-Ab-1/ GM-Tg-bovg-T97071-Ab-2; GM-Tg-equg-T97071-Ab-1/ GM-Tg-equg-T97071-Ab-2
Products NameAnti-GCPII/FOLH1 monoclonal antibody
Formatmab
Target NameGCPII
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GCPII benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-434Pre-Made Pelgifatamab biosimilar, Whole mAb ADC, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody
    BiosimilarGMP-Bios-INN-979Pre-Made Rosopatamab Tetraxetan Biosimilar, Whole Mab Adc, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody Drug Conjugate
    BiosimilarGMP-Bios-INN-771Pre-Made Capromab Biosimilar, Radiolabelled Antibody, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody
    BiosimilarGMP-Bios-ab-709Pre-Made Voxalatamab biosimilar, Whole mAb, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-006Pre-Made Acapatamab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-ab-496Pre-Made Rosopatamab biosimilar, Whole mAb, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody
    BiosimilarGMP-Bios-ab-429Pre-Made Pasotuxizumab biosimilar, Bispecific scFv, Anti-FOLH1/GCPII;CD3E Antibody: Anti-FGCP/GCP2/NAALAD1/PSM/PSMA/mGCP;T3E/TCRE/IMD18 therapeutic antibody
    BiosimilarGMP-Bios-INN-958Pre-Made Pelgifatamab Corixetan Biosimilar, Whole Mab Adc, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody Drug Conjugate
    Target AntigenProducts DevelopingMulti-species FOLH1/ GCPII/ FGCP VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLP002846human FOLH1 Lentivirus particle
    ORF Viral VectorpGMLP002846human FOLH1 Lentivirus plasmid
    ORF Viral VectorpGMLPm003113mouse Folh1 Lentivirus plasmid
    ORF Viral VectorvGMLPm003113mouse Folh1 Lentivirus particle


    Target information

    Target IDGM-T97071
    Target NameGCPII
    Gene ID2346,53320,85309
    Gene Symbol and SynonymsFGCP,FOLH,FOLH1,GCP2,GCPII,mGCP,mopsm,Naalad,NAALAD1,PSM,PSMA
    Uniprot AccessionQ04609,P70627
    Uniprot Entry NameFOLH1_HUMAN,FOLH1_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseProstate Cancer
    Gene EnsemblENSG00000086205
    Target ClassificationCheckpoint-Immuno Oncology

    The target: GCPII, gene name: FOLH1, also named as FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP. This gene encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. The protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-l-aspartyl-l-glutamate and is expressed in a number of tissues such as prostate, central and peripheral nervous system and kidney. A mutation in this gene may be associated with impaired intestinal absorption of dietary folates, resulting in low blood folate levels and consequent hyperhomocysteinemia. Expression of this protein in the brain may be involved in a number of pathological conditions associated with glutamate excitotoxicity. In the prostate the protein is up-regulated in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer. This gene likely arose from a duplication event of a nearby chromosomal region. Alternative splicing gives rise to multiple transcript variants encoding several different isoforms. [provided by RefSeq, Jul 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.